Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

26.72
-0.3300-1.22%
Post-market: 26.720.00000.00%19:30 EDT
Volume:1.49M
Turnover:40.18M
Market Cap:2.76B
PE:-7.84
High:27.50
Open:27.41
Low:26.70
Close:27.05
52wk High:28.23
52wk Low:8.20
Shares:103.41M
Float Shares:95.05M
Volume Ratio:1.26
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:6.86
PE(LYR):-8.76

Loading ...

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

THOMSON REUTERS
·
Aug 20

Nurix Therapeutics (NRIX) Starts Phase 3 And Lands Sanofi Milestone, Is The Valuation About Right?

Simply Wall St.
·
Aug 18

Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche

Simply Wall St.
·
Aug 13

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Nurix Therapeutics is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 11

RBC Adjusts PT on Nurix Therapeutics to $36 From $33, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 10

How Investors May Respond To Nurix Therapeutics (NRIX) Advancing Bexobrutideg Into Registrational Phase 3 With Roche

Simply Wall St.
·
Aug 06

Nurix CSO Gwenn Hansen Sells 4,111 Shares for $100,068.32

Reuters
·
Aug 05

Nurix Therapeutics Price Target Maintained with a $34.00/Share by Needham

Dow Jones
·
Aug 04

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a Stat6 Degrader

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics - Has Received About $139 Mln Under 2019 Sanofi Collaboration

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics - Eligible for About $453 Mln in Future Stat6 Milestones and Potential Royalties

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics Enrolls First Patient in Phase 3 Blood Cancer Trial

MT Newswires Live
·
Aug 04

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 Daybreak Cll-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

THOMSON REUTERS
·
Aug 04

Nurix Therapeutics Chief Legal Officer Christine Ring Disposes of 16,589 Common Shares Worth $382,324.26

Reuters
·
Aug 04

Nurix Therapeutics is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 29

Nurix Therapeutics is Maintained at Buy by UBS

Dow Jones
·
Jul 23

UBS Lifts Nurix Therapeutics Price Target to $31 From $23, Maintains Buy Rating

MT Newswires Live
·
Jul 22

Nurix Therapeutics, Roche Partner to Co-develop BTK Degrader Bexobrutideg in Deal Worth up to $2.3 Billion

Reuters
·
Jul 22

Nurix Therapeutics Announces Hsr Clearance of Global Collaboration with Roche to Co-develop and Co-commercialize Potential Best-in-class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

THOMSON REUTERS
·
Jul 22